Symtuza FDA Approval History
FDA Approved: Yes (First approved July 17, 2018)
Brand name: Symtuza
Generic name: cobicistat, darunavir, emtricitabine and tenofovir alafenamide
Dosage form: Tablets
Company: Janssen Pharmaceuticals, Inc.
Treatment for: HIV Infection
Symtuza (darunavir, cobicistat, emtricitabine and tenofovir alafenamide) is a once daily, single-tablet regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) in treatment-naïve and certain virologically suppressed adults.
Development Timeline for Symtuza
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.